Advertisement

Topics

Clinical Trials About "Amphastar Pharmaceuticals Release Fourth Quarter Earnings Hold Conference" RSS

08:35 EST 17th November 2018 | BioPortfolio

We list hundreds of Clinical Trials about "Amphastar Pharmaceuticals Release Fourth Quarter Earnings Hold Conference" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Amphastar Pharmaceuticals Release Fourth Quarter Earnings Hold Conference" on BioPortfolio

We have published hundreds of Amphastar Pharmaceuticals Release Fourth Quarter Earnings Hold Conference news stories on BioPortfolio along with dozens of Amphastar Pharmaceuticals Release Fourth Quarter Earnings Hold Conference Clinical Trials and PubMed Articles about Amphastar Pharmaceuticals Release Fourth Quarter Earnings Hold Conference for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Amphastar Pharmaceuticals Release Fourth Quarter Earnings Hold Conference Companies in our database. You can also find out about relevant Amphastar Pharmaceuticals Release Fourth Quarter Earnings Hold Conference Drugs and Medications on this site too.

Showing "Amphastar Pharmaceuticals Release Fourth Quarter Earnings Hold Conference" Clinical Trials 1–25 of 2,800+

Relevant

The Effect Of Stretching Exercise on Pectoralis Minor Myofascial Latent Trigger Points

This randomised-controlled trial investigates whether a single intervention of manual pressure release combined with stretching exercise has an effect on muscle length, pain perception threshold, and respiratory function in subjects with latent myofascial trigger point in the pectoralis minor muscle or not. First quarter of the participants will receive a single intervention of manual pressure release combined with contract-relax PNF stretching exercise of pectoralis minor musc...


Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions

The objective of this study is to evaluate the comparative bioavailability between bupropion hydrochloride 300 mg extended release tablets (Teva Pharmaceuticals USA) and Wellbutrin XL® 300 mg extended release tablets (Biovail Pharmaceuticals, Inc.) at steady-state in patients under fasting conditions.

Parent/Caregiver Conference Attendance Feasibility

This study will assess and evaluate conference attendance feasibility and will gather feedback about preferences and barriers to attendance at the American Society for Nutrition annual conference.


Health Education for Physiotherapy in Soccer Players

INTRODUCTION. Health education based on interventions with new information and communication technologies. OBJECTIVE. To compare the effectiveness of an educational physiotherapy intervention in footballers, in face-to-face mode (conference) versus an intervention mediated by ICT, on the risk of medical injury with the Functional Movement Screen [FMS]. MATERIAL AND METHODS. A randomized clinical trial (RCT) was carried out. The population consisted of 100 participants d...

A Study Investigating the Effects of Niagen™ in Healthy Adults.

This study will evaluate the effect of repeated doses of Niagen™ on Niagen™ metabolite concentrations in blood, urine and muscle. There will be 3 doses of Niagen™ compared to a placebo. One quarter of subjects will receive the low dose of Niagen™, one quarter will receive the moderate dose of Niagen™, one quarter will receive the higher dose of Niagen™ and one quarter will reveive the placebo.

A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-Fasting Conditions

The purpose of this study is compare the relative bioavailability of Nifedipine ER tablets 60 mg by Abrica Pharmaceuticals LLLP with that of ADALAT® CC Extended Release Tablets 60 mg by Bayer Pharmaceuticals Corporation, Bayer HealthCare following a single oral dose (1 x 60 mg tablet) in healthy adult volunteers under non-fasting conditions

Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 3 mg Alprazolam Extended Release Tablets manufactured and distributed by TEVA Pharmaceuticals USA with that of 3 mg XANAX XR® Tablets by Pharmacia & Upjohn Company following a single oral dose (1 x 3 mg extended release tablet) in healthy adult subjects administered under non-fasting conditions.

Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 3 mg Alprazolam Extended Release Tablets manufactured and distributed by TEVA Pharmaceuticals USA with that of 3 mg XANAX XR® Tablets by Pharmacia & Upjohn Company following a single oral dose (1 x 3 mg extended release tablet) in healthy adult subjects administered under fasting conditions.

Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg

The objective of this study was to investigate the bioequivalence of nisoldipine extended-release 30 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release 30 mg tablet (manufactured for First Horizon) following a single, oral 30 mg (1 × 30 mg tablet) dose administration in healthy adult subjects under fasting conditions.

Lansoprazole 30 mg DR Capsule Fasting Study

The object of this study is to compare the relative bioavailability of lansoprazole 30 mg delayed-release capsules (manufactured by TEVA Pharmaceutical Industries, Ltd. and distributed by TEVA Pharmaceuticals USA) with that of PREVACID® capsules (TAP Pharmaceuticals, Inc.) in healthy, adult, subjects under fasting conditions.

Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)

The purpose of this study is to demonstrate the relative bioavailability of Naproxen delayed-release tablets (375 mg).

A Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed Release (DR) Capsules (Takeda Pharmaceuticals America Inc., USA)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Dexlansoprazole from Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed release Capsules (Takeda Pharmaceuticals America Inc., USA)

Lansoprazole 30 mg DR Capsule Fasting Replicate Sprinkle Study

The object of this study is to compare the relative bioavailability of lansoprazole 30 mg delayed-release capsules (manufactured by TEVA Pharmaceutical Industries, Ltd. and distributed by TEVA Pharmaceuticals USA) with that of PREVACID® capsules (TAP Pharmaceuticals, Inc.) in healthy, adult, subjects under fasting conditions with dosing by applesauce-sprinkle method.

Minocycline HCl Extended Release Tablets 135 mg Oral Bioequivalence Study

To determine single-dose oral bioequivalence of Minocycline HCl Extended Release Tablets 135 mg manufactured by Amneal Pharmaceuticals Co.(I)Pvt. Ltd., India and SOLODYN® (minocycline hydrochloride) Extended Release Tablets 135 mg Manufactured for Medicis, The Dermatology Company, Scottsdale, AZ 85256, by Wellspring Pharmaceutical Canada Corp., Oakville, Ontario L6H 1M5 in normal, healthy, adult, human subjects under fasting condition.

Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers

The objective of this study was to investigate the bioequivalence of nisoldipine extended-release 40 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release 40 mg tablet (manufactured for First Horizon) following a single, oral 40 mg (1 × 40 mg tablet) dose administration in healthy adult subjects under fed conditions.

Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults

The primary objective of this study was to compare the single-dose relative bioavailability of Alpharma Branded Products Division (Kadian®) and Ligand® Pharmaceuticals Inc. (AVINZA®) 30 mg morphine sulfate sustained-release capsules in healthy adult volunteers under fed conditions. The secondary objective of this study was to evaluate the adverse events associated with each of these 2 different morphine sulfate modified-release commercial formulations

Analgesic Potentials of Preoperative Pregabalin,Magnesium Sulphate and Their Combination in Acute Post-thoracotomy Pain

This study evaluates the effect of giving preoperative adjuvant drug as pregabalin or magnesium sulphate or a combination of both drugs to decrease postoperative morphine consumption and pain intensity in the first 24 hours in postoperative period . quarter of patients receive single dose oral pregabalin 300mg 1 hour preoperatively ,other quarter receive single intravenous Magnesium sulphate 50mg per Kg over 200ml saline over 20 minutes preoperatively , other quarter receive co...

A Relative Bioavailability Study of Acetaminophen 650 mg Extended Release Gelcaps Under Fasting Condition

The study was conducted as an open labeled, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioavailability study comparing acetaminophen extended release gelcaps 650 mg of OHM Laboratories Inc. with Tylenol® Arthritis Pain caplets 650 mg of McNeil Consumer & Specialty Pharmaceuticals, in healthy, adult, human, male subjects under fasting condition.

Informed Consent in Pediatric Cancer Trials

Background: - Informed consent is the process by which prospective participants in clinical trials learn about clinical research in order to decide whether they want to enroll in the study. It consists of meetings and discussions with the health care team. - Phase I clinical trials are designed to determine what dose of an investigational agent is safe to administer to patients. Objectives: - To study communication, comprehension and deci...

E-alcohol Therapy - an Evaluation of Alcohol Therapy Delivered Via Video Conference

The study evaluates whether the introduction of e-alcohol therapy (alcohol therapy delivered via video conference) can break with some of the barriers related to alcohol treatment and thereby appeal to people with a problematic alcohol use (Alcohol Use Disorder Test score ≥ 8). The study aims to evaluate the effect of e-alcohol therapy on initiation, treatment compliance and alcohol intake as compared to treatment as usual .

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were separated by a washout period of 11 days.

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were separated by a washout period of 11 days.

HIV-1 Specific Immune Responses in Thai Individuals With HIV Dementia

A total of 60 participants will be enrolled. They will be in 3 groups 1. ARV-naïve, HIV-positive ≥ 20 year of age with HAD (n=20) who intend to start ARV 2. ARV-naïve, HIV-positive ≥ 20 year of age without HAD (n=20), who intend to start ARV 3. HIV-negative ≥ 20 year of age (n=20). The protocol team will work with the primary care physician to ensure that the subjects receive standard HIV and ARV care; however, initiation of ARV is not a requirement ...

Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma

This study seeks to determine the optimum dose frequency of 5-Azacytidin (5-AZA) infusions into the fourth ventricle of the brain. The study's primary objective is to establish the maximum tolerated dose for infusions of 5-Azacytidine into the fourth ventricle in patients with recurrent ependymoma. The study's secondary objective is to assess the antitumor activity of 5-Azacytidine infusions into the fourth ventricle based upon imaging studies and cytology.

The Economic and Cognitive Effects of Pain Reduction

Physical pain is a common but largely overlooked aspect of the lives of the poor. Not only does pain directly reduce life quality and happiness, it may also hamper cognitive function and, consequently, decision-making, productivity, and earnings. Workers with chronic pain may work fewer days, take longer breaks, and make less-considered choices regarding inputs; all outcomes that would reduce output and lead to greater impoverishment or impede the productivity and profitability...


More From BioPortfolio on "Amphastar Pharmaceuticals Release Fourth Quarter Earnings Hold Conference"

Advertisement
Quick Search
Advertisement
Advertisement